Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could heart failure drugs boost oral Iron's power against anemia?

NCT ID NCT07708025

Disease control Sponsor: Universidade do Porto Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study looks at whether heart failure patients with iron deficiency anemia respond better to oral iron supplements when they are also taking a type of heart medication called SGLT2 inhibitors. Participants take oral iron for three to four months, then pause treatment while doctors monitor their blood. The goal is to see if the heart drug helps the body use iron more effectively to raise hemoglobin levels.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
oral iron supplementation (hydroxide polymaltose or ferrous sulfate)
What this could lead to
If successful, it could show that SGLT2i drugs improve how well oral iron works for heart failure patients with anemia, potentially simplifying treatment.
What could go wrong
This is a small, early-phase study with only 55 participants, and results may not apply to all heart failure patients. Oral iron absorption may still be limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

55 people

The number who actually took part.

Started

Sep 2025

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\) Previous diagnosis of heart failure, irrespective of ejection fraction; * 2\) Iron deficiency anemia defined as hemoglobin \<13 g/dL in men or \<12 g/dL in women, with transferrin saturation (TSAT) \<20%; * 3\) Ongoing treatment with an SGLT2 inhibitor (SGLT2i) for more than 3 months at the time of enrollment. Exclusion Criteria: * 1\) Concomitant use of intravenous iron, erythropoiesis-stimulating agents (ESAs), red blood cell transfusions, or other blood products within 3 months before enrollment; * 2\) Severe anemia, defined as hemoglobin \<7 g/dL or clinical indication for transfusion; * 3\) Relevant intercurrent illnesses associated with inflammatory response (e.g., infection, acute kidney injury, or acute decompensated heart failure) within 3 months before enrollment; * 4\) Confirmed or suspected active bleeding; * 5\) End-stage renal disease or receiving renal replacement therapy; * 6\) History of any type of active cancer; * 7\) History of solid or non-solid organ transplantation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anemia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anemia heart failure iron deficiency anemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anemia Heart failure

Contacts and locations

Locations

  • Unidade Local de Saúde São João

    Porto, 4200-319, Portugal

More trials for these conditions

Other studies related to the condition(s) this trial covers.